Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
441 Leser
Artikel bewerten:
(2)

The Biofactory Unveils New "Plug and Play" System Capable of Instantly Isolating Healthcare Facilities

SINGAPORE, Sept. 10, 2020 /PRNewswire/ -- The Biofactory, a Singapore-based biomedical technology manufacturer, unveiled a new portable "plug and play" system to isolate positively pressured healthcare facilities (Operating Theatres, Procedure Rooms and Intensive Care Units) and normal pressured facilities (Wards, Clinics, and Laboratories), in just an hour. The System of Portable AnteRoom for Containment, or SPARCX (SG-SPARC), is a breakthrough patented technology co-developed with the Department of Anaesthesiology, Singapore General Hospital (SGH) to better protect healthcare workers, patients and visitors.

Fig 1: Graphic Demonstrating Airflow within SPARCX Models

SPARCX (SG-SPARC) system is installed within the only entrance to the room and features advanced patented technology: a novel air decontamination protocol enabled by a powerful medical grade air filtration unit capable of up to 350 air exchanges per hour, continuous negative pressure and intelligently integrated airtight doors. These features allow it to isolate most rooms from the corridor regardless of the room's internal pressure - positive (typically hardest to isolate), normal or negative: thereby preventing transmission of airborne diseases despite room-to-room movement and allow rapid conversion of existing infrastructure to meet sudden surges of infectious patients.

"We had seen how hospitals overseas struggled when they ran out of negative pressure isolation rooms during the COVID-19 pandemic. With SG-SPARC (SPARCX), we save time and money by avoiding the need to build temporary or new permanent structures, while protecting healthcare workers from any infected risks," said Dr Mavis Teo, Consultant, Department of Anaesthesiology, SGH, who is a co-investigator of the project.

Installation is simple and no renovation is required. To isolate a room, the telescopic SPARCX (SG-SPARC) System is fitted within the entrance of the room and the edges are sealed off. It took one hour to set up the 70kg SPARCX (SG-SPARC) system at SGH's Medical ICU, and one more will be added soon.

A larger model of SPARCX (SG-SPARC) System has also been developed and deployed to isolate the positively pressured operating theatre (OT). This model is able to fit an ICU bed, a ventilator and necessary equipment in order to enable healthcare workers to perform their jobs safely when handling any infected or suspected patients in the OT. The 150kg SPARCX (SG-SPARC) OT System measures 3.8m by 1.6m with a height of 2m, and only takes two hours to set up.

"With a special emphasis on rapid deployment, reliability and user-friendliness, installation is fuss-free and can be done quickly and simply- anywhere in the world. We have received strong interest from local and overseas buyers, and we are ready to meet the global demand for SPARCX Systems," said Mr Gabriel Tan, Programme Director, The Biofactory.

To evaluate SPARCX (SG-SPARC) System's virus containment efficacy, A*STAR's Institute of Bioengineering & Nanotechnology (IBN) released live non-pathogenic viruses into a simulated patient room outfitted with the SPARCX (SG-SPARC) system. No viruses were found to have leaked from the patient room to the corridor.

"To our knowledge, this is the first time that such portable anteroom models were tested using live non-pathogenic viruses in Singapore. This method allows for more accurate testing compared to conventional methods, as it facilitates measurement of how many live virus particles are present," said Professor Yang Yi Yan, Covering Executive Director, IBN, A*STAR.

The SPARCX (SG-SPARC) System is the result of an innovation research project funded by SingHealth Duke-NUS's Urgent COVID-19 Research Fund.

For more information: https://www.thebiofactory.com/

Media Contact:

Marcus Tan
contact@thebiofactory.com
+65-6397-5155

Company Profile

The Biofactory Pte Ltd is one of the leading biomedical incubators and manufacturers in Singapore. The company was established in 2009 to commercialize and manufacture biomedical products within its ISO-13485 certified facility.

Photo - https://mma.prnewswire.com/media/1251115/Quick_conversion.jpg

© 2020 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.